GSK plc (GSK) Stock Analysis

GSK’s competitive edge rests on a combination of scientific depth, focused portfolio strategy, and operational scale. The company is a global leader in vaccines and HIV therapeutics, with its ViiV Healthcare joint venture (78% GSK-owned) holding a dominant position in long-acting HIV treatments—Cabenuva and Apretude—where GSK faces limited direct competition from Pfizer, Gilead, and Merck. In vaccines, GSK’s Shingrix (shingles) and Arexvy (RSV) are category leaders, with Shingrix generating £3.6 billion in 2025 sales and Arexvy recently expanding its approved age range.

GSK’s R&D investment is substantial (£7.5 billion in 2025, up 18%), supporting a pipeline of 58 assets, over half sourced through business development. The company’s focus on specialty medicines (oncology, respiratory, immunology) has driven double-digit sales growth in these segments, outpacing peers such as Sanofi and AstraZeneca in respiratory and immunology. GSK’s early adoption of AI and data-driven R&D is intended to accelerate drug development and improve trial efficiency, a capability not yet matched by all rivals.

Operationally, GSK’s global manufacturing network and supply chain resilience—evidenced by a 99% on-time delivery rate—support reliable product availability. The company’s culture emphasizes accountability and responsible business, reflected in its 92% achievement of ESG targets in 2025. However, GSK faces ongoing pricing pressure and patent expiries, particularly in HIV, where competition from generics and new modalities is intensifying.